Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05339594 · ClinicalTrials.gov registry record
REINVENT Registry (Registry of the Nerve Gap Repair From Integra)
A clinical trial, sponsored by Integra LifeSciences Corporation.
- Terminated
- Registry status
- 17
- Enrollment target
NCT05339594: Clinical Trial study, sponsored by Integra LifeSciences Corporation.
NCT05339594 is a clinical trial that was terminated before completion, run by Integra LifeSciences Corporation. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05339594 was terminated before completion, sponsored by Integra LifeSciences Corporation.
- TERMINATED
- Registry status
- 17 participants
- Enrollment target
Study Summary
This is a prospective, multi-center, observational registry designed to evaluate two of Integra's collagen nerve gap repair products (NeuraGen® Nerve Guide and NeuraGen® 3D Nerve Guide Matrix). This registry will collect data on the outcome measures throughout the follow-up period for each patient. Data will be collected per standard of care.
Primary Outcome
The primary endpoint success is when each subject reaches meaningful recovery, which is defined as an MRC score of S3+ or S4 (fair, good or excellent 2PD) of the pulp assessment of the distal phalanx of the affected digit(s).
Interventions
- DEVICE NeuraGen
- DEVICE NeuraGen 3D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2022-05-30 |
| Est. Completion | 2024-06-03 |
Why NCT05339594 stopped before completion
NCT05339594 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 17 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which NeuraGen is the first listed.
NCT05339594 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05339594 about?
NCT05339594 is a clinical study titled "REINVENT Registry (Registry of the Nerve Gap Repair From Integra)". This is a prospective, multi-center, observational registry designed to evaluate two of Integra's collagen nerve gap repair products (NeuraGen® Nerve Guide and NeuraGen® 3D Nerve Guide Matrix). This registry will collect data on the outcome measures throughout the follow-up period for each patient. ...
What is the current status of trial NCT05339594?
This trial is currently terminated. The enrollment target is 17 participants. The study started on 2022-05-30. Estimated completion is 2024-06-03.
What interventions are being tested in trial NCT05339594?
The interventions under investigation include: NeuraGen (DEVICE), NeuraGen 3D (DEVICE).
Who is sponsoring clinical trial NCT05339594?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI